Methotrexat Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition reduces the proliferation of rapidly dividing cells, such as immune cells in inflammatory diseases and cancer cells in malignancies, thereby providing therapeutic benefit.

The specific dose of Methotrexat Ebewe is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and treatment goals. Healthcare providers calculate the appropriate regimen and adjust it according to clinical response and laboratory monitoring.

Methotrexat Ebewe is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexat Ebewe belongs to the antimetabolite class, differing from alkylating agents or taxanes in its mechanism of folate antagonism. Compared with newer biologics, methotrexate is less expensive and administered intravenously, but it requires more intensive monitoring for hematologic and hepatic toxicity.

Methotrexat Ebewe should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken vigorously, and it should remain in its original packaging to maintain stability until it is prepared for intravenous administration.

Methotrexat Ebewe is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a set period according to the prescribing protocol, with appropriate pre‑medication and monitoring as required.

The most serious risks include bone marrow suppression leading to severe pancytopenia, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Prompt recognition and regular laboratory monitoring are essential to mitigate these hazards.

Methotrexat Ebewe is contraindicated in pregnant or lactating women, patients with severe hepatic or renal dysfunction, those with known hypersensitivity to methotrexate, and individuals with active, uncontrolled infections. Clinicians must also avoid use in patients receiving certain interacting medications without careful monitoring.